Search companies or stocks...
The financial statements for SANA (SANA) provide a snapshot of revenue trends, balance-sheet strength, and cash flow quality. Reviewing these together helps investors evaluate earnings durability, capital structure, and whether operating cash flow supports long-term business growth.
See stock fair value and complete historical financials—premium unlocks deeper tables and metrics.
| NKTR Nektar Therapeutics | $64.88 -0.20% |
| SNDX Syndax Pharmaceuticals, Inc. | $19.59 -0.81% |
| RLAY Relay Therapeutics, Inc. | $14.05 +1.08% |
| INBX Inhibrx Biosciences, Inc. | $104.01 +0.03% |
| OCS Oculis Holding AG | $22.70 -23.42% |
| NRIX Nurix Therapeutics, Inc. | $17.76 +0.51% |
| Peer | Price | Change | Market Cap | PE | EPS | Div Yield (TTM) | Analyst Rating | Volume |
|---|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | $64.88 | -0.20% | 1.27 B | -8.18 | -7.93 | 0.00% | Buy | 929 |
| SNDX Syndax Pharmaceuticals, Inc. | $19.59 | -0.81% | 1.74 B | -7.02 | -2.79 | 0.00% | Buy | 805 |
| RLAY Relay Therapeutics, Inc. | $14.05 | +1.08% | 2.69 B | -9.01 | -1.56 | 0.00% | Buy | 3.29 |
| INBX Inhibrx Biosciences, Inc. | $104.01 | +0.03% | 1.53 B | -12.40 | -8.39 | 0.00% | Hold | 182 |
| OCS Oculis Holding AG | $22.70 | -23.42% | 1.30 B | -10.56 | -2.15 | 0.00% | Buy | 1.52 |
| NRIX Nurix Therapeutics, Inc. | $17.76 | +0.51% | 1.54 B | -5.60 | -3.17 | 0.00% | Buy | 1.09 |
Review SANA's latest balance sheet, income statement, and cash flow to understand its profitability, revenue trends, and financial health. These metrics are essential for evaluating short-term performance and long-term stability.
Analyzing historical revenue and net income shows growth trends and business performance. Consistent growth indicates operational strength, while declines may signal challenges that investors should consider.
Cash flow statements reveal how SANA generates and uses cash. Strong operating cash flow and sufficient liquidity suggest the company can fund operations, pay dividends, and handle debt effectively.
Comparing key metrics like revenue growth, profit margins, and debt levels with competitors helps investors assess whether SANA is outperforming or lagging within its sector.
By analyzing margins, ROE, ROIC, and cash generation over multiple periods, investors can evaluate whether SANA's profits are repeatable and supported by strong fundamentals.
